TherapeuticsMD (TXMD) recently reported their Q4/2019 earnings that revealed that their 2019 efforts have set up 2020 to be a year of substantial revenue growth. The company was dedicated to launching their product portfolio, confirming payer wins, and transforming TXMD's overall focus from clinical to a commercial company. These efforts led to the company reporting that they topped their TXMD's fourth-quarter guidance and hit the top-end of TXMD's full-year guidance. As a result, the company fulfilled the conditions with TPG Sixth Street Partners to access another $50M tranche to be added to the